• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Drugs

  • Print
  • Share
  • E-mail

Section Contents Menu

Drug Safety and Availability

FDA Drug Safety Newsletter Index, Volume 1, 2007-2008

ABCDEFGHIJKLM
NOPQRSTUVWXYZ


 

An index to brand-name drugs, generic drugs and health issues discussed in Drug Safety Newsletter articles. A list of drug safety alerts and communications can be found on the Index to Drug-Specific Information.

Page numbers refer to the print version (PDF).
 



A

Acute Pancreatitis
Exenatide, 12-14
Adalimumab
Serious Skin Reactions, 18-22
Alimta, 30-32
Amiodarone, 46-48
Aplastic Anemia
Temozolomide, 7-8



B

Byetta, 12-14



C

Carbamazepine
HLA-B*1502, 35-37
Stevens-Johnson Syndrome, 35-37
Toxic Epidermal Necrolysis, 35-37
Carbatrol, 35-37
Cialis, 15-17
Cordarone, 46-48
Cymbalta, 22-24



D

Deferasirox, 8-9
Duloxetine, 22-24



E

Enbrel, 18-22
Equetro, 35-37
Erythema Multiforme
Lenalidomide, 43-46
Etanercept
Serious Skin Reactions, 18-22
Exenatide
Acute Pancreatitis, 12-14
Exjade, 8-9
Extraneal, 49



G

Glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ), 49
Glucose-dye-oxidoreductase (GDO), 49



H

Hearing Loss
PDE-5 Inhibitors, 15-17
Sildenafil, 15-17
Tadalafil, 15-17
Vardenafil, 15-17
HLA-B*1502
Carbamazepine, 35-37
Humira, 18-22
Hypoglycemia
Icodextrin, 49



I

Icodextrin
Extraneal, 49
Infliximab
Serious Skin Reactions, 18-22



L

Lariam, 41-43
Lenalidomide
Serious Skin Reactions, 43-46
Levitra, 15-17



M

Medication Errors, 50-52
Mefloquine Hydrochloride
Pneumonitis, 41-43
Modafinil
Serious Skin Reactions, 5-7



N

Natalizumab
Serious Liver Injury, 33-35



P

Pacerone, 46-48
PDE-5 Inhibitors
Hearing Loss, 15-17
Pemetrexed
Radiation Recall, 30-32
Pharmacogenomics, 24-26
PML (Progressive Multifocal Leukoencephalopathy), 3-5
Pneumonitis
Mefloquine Hydrochloride, 41-43
Progressive Multifocal Leukoencephalopathy (PML), 3-5
Provigil, 5-7



R

Radiation Recall
Pemetrexed, 30-32
Remicade, 18-22
Revatio, 15-17
Revlimid, 43-46
Rhabdomyolysis
Amiodarone, 46-48
Simvastatin, 46-48
Zocor, 46-48
Vytorin, 46-48
Simcor, 46-48
Cordarone, 46-48
Pacerone, 46-48
Rituxan, 3-5
Rituximab
Progressive Multifocal Leukoencephalopathy (PML), 3-5



S

Serious Liver Injury
Natalizumab, 33-35
Serious Skin Reactions
Adalimumab, 18-22
Etanercept, 18-22
Infliximab, 18-22
Lenalidomide, 43-46
Modafinil, 5-7
TNF-α Antagonists, 18-22
Sildenafil
Hearing Loss, 15-17
Simcor, 46-48
Simvastatin, 46-48
Stevens-Johnson Syndrome
Carbamazepine, 35-37
Lenalidomide, 43-46



T

Tadalafil
Hearing Loss, 15-17
Tegretol, 35-37
Temodar, 7-8
Temozolomide
Aplastic Anemia, 7-8
TNF-α Antagonists
Serious Skin Reactions, 18-22
Toxic Epidermal Necrolysis
Carbamazepine, 35-37
Lenalidomide, 43-46
Tysabri, 33-35



V

Vardenafil
Hearing Loss, 15-17
Viagra, 15-17
Vytorin, 46-48



Z

Zocor, 46-48